Marco Meier

Marco Meier has a wealth of work experience in the field of biotechnology. Marco began their career in 2003 as a Lab Technician at Novartis Pharmaceuticals, where they were responsible for microbial limit assays and their validations. In 2004, they moved to Cytos Biotechnology AG as a Lab Technician III, where they were responsible for histology and immunohistology, mouse in vivo procedures, and in vitro assays. In 2010, they joined Vaxine Pty Ltd as a Senior Lab Technician, where they were a leader in mouse in vivo tumor related experiments, analysis of clinical trial human blood samples, and research of different Adjuvants (Advax) formulations. Marco then moved to 4-Antibody AG in 2011 as a Junior Manager - Lab head screening unit, and was then acquired by Agenus in 2014, where they worked as an Associate Scientist using mammalian cell display to screen for antibody and T cell receptors (TCR). In 2017, they joined NBE-Therapeutics as a Senior Laboratory Technician, and in 2019, they became the Head of in vivo unit at NBE-Therapeutics AG.

Marco Meier completed an apprenticeship as a Biological Lab Technician at Aprentas Basel from 2000 to 2003, specializing in Biology/Biological Sciences, General.